Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.
Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver stiffness and pruritis, with a favorable safety profile.
Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.
Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 150 points on Wednesday. The Dow traded up 0.46% to 34,989.30 while the NASDAQ rose 0.16% to 14,116.28. The S&P 500 also rose, gaining, 0.26% to 4,507.40.
U.S. stocks traded higher this morning, with the Dow Jones gaining around 90 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.27% to 34,922.07 while the NASDAQ rose 0.36% to 14,144.63. The S&P 500 also rose, gaining, 0.27% to 4,507.75.
